PT33 Cost-Effectiveness of Pembrolizumab Plus Chemotherapy, With or Without Bevacizumab for the First-Line Treatment of PD-L1-Positive Patients With Persistent, Recurrent, or Metastatic Cervical Cancer in France
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.1030
https://www.valueinhealthjournal.com/article/S1098-3015(23)04160-8/fulltext
Title :
PT33 Cost-Effectiveness of Pembrolizumab Plus Chemotherapy, With or Without Bevacizumab for the First-Line Treatment of PD-L1-Positive Patients With Persistent, Recurrent, or Metastatic Cervical Cancer in France
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)04160-8&doi=10.1016/j.jval.2023.09.1030
First page :
Section Title :
Open access? :
No
Section Order :
10525